Chest Infections |

The Incidence of Multidrug Resistant Tuberculosis Among Patients Receiving Standardized Treatment Regimen for Suspected MDR-TB FREE TO VIEW

Augusto Sablan*, MD; Joven Gonong, MD; Lawrence Raymond, MD; Vivian Lofranco, MD; Vincent Balanag, MD
Author and Funding Information

Lung Center of the Philippines, Quezon City, Philippines

Chest. 2012;142(4_MeetingAbstracts):209A. doi:10.1378/chest.1387529
Text Size: A A A
Published online


SESSION TYPE: Respiratory Infections Posters I

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: To determine the incidence of MDR-TB among patients receiving standardized treatment regimen for suspected MDR-TB cases.

METHODS: This is Descriptive study. The study included 256 patients who were enrolled to receive standardized treatment regimen for suspected MDR-TB from the period of June 2010 until December 2010.

RESULTS: 256 patients received standardized treatment regimen,179 patients have available culture and DST results, 76 patients still have pending culture and DST results.Of the 179 patients, 101 belonged to STR B and 78 to STR A. The incidence of MDR-TB was 81.2%(82 out of 101) for STR B and 39.7 % (31 out of 78) for STR A. MDR-TB occurred most frequently among Category 1 failure 94% (17 of 18 patients), followed by Category 2 failure 90.1% (10 of 11 patients) and 76.3% (55 of 72 patients) for patients with Multiple non-DOTS treatment. Incidence of MDR-TB was 55% and 30.4% for Category 2 relapse and single non-DOTS treatment, and respectively 45.5% and 33.3% for Category 1 RAD and Category 1 relapse.

CONCLUSIONS: MDR-TB occurs more frequently among the standardized regimen B group (category I failure, category II failure, and other Non-DOTS with multiple treatment).

CLINICAL IMPLICATIONS: Initiation of standardized regimen for MDR-TB for patients with Category I failure, Category II failure, category II relapse and those with Non-DOTS with multiple treatment while awaiting the results of the DST . Category II treatment regimen,should be used in category I RAD and category I relapse pending culture and DST results.

DISCLOSURE: The following authors have nothing to disclose: Augusto Sablan, Joven Gonong, Lawrence Raymond, Vivian Lofranco, Vincent Balanag

No Product/Research Disclosure Information

Lung Center of the Philippines, Quezon City, Philippines




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543